The short version of glucagon receptor fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
| Property | Value | Notes |
|---|---|---|
| Molecule class | Synthetic peptide | Engineered triple receptor agonist |
| Molecular weight | Approximately 4731 Da | Reported value; depends on form |
| Receptor targets | GLP-1, GIP, glucagon | Simultaneous activation |
| Development code | LY3437943 | Internal company designation |
| Current status | Investigational | No approved indication reported |
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
=== Drosophila melanogaster === Flies lacking in FICD (CG9523) have been described as blind. Initially, this defect was attributed to a role for FICD on the cell surface of capitate projections - a putative site of neurotransmitter recycling however a later study implicated FICD-mediated AMPylation of BiP Thr366 in the visual problem
== Unlikely scenarios == While the scientific consensus is that SARS-CoV-2 derived from viruses hosted in bats, the precise means by which this occurred has been sometimes subject to speculation. Below are some scenarios judged to be unlikely.
The United States Armed Forces' Meal, Ready-to-Eat (MRE) is packaged similarly to the Canadian ration. Each sealed plastic bag contains one entire precooked meal, with a number of supplements and accessories. The original 12 menus have been expanded to 24 and now contain a variety of ethnic and special request items as well. Kosher/Halal and Vegetarian menus are also provided. Each meal bag contains an 8-ounce (230 g) main course (packaged in a four-layer plastic and foil laminate retort pouch), 8 hardtack crackers, some form of spread (cheese, peanut butter, or jelly), a fruit-based beverage powder, some form of dessert (cake, candy, cookies, or fruit), and an accessory packet containing coffee or tea, creamer, sugar, salt, matches, a plastic spoon, and toilet paper. A chemical heater is packed with every meal. The First Strike Ration (FSR) is a compact, eat-on-the-move ration to be used for no more than three days during initial periods of highly intense, highly mobile combat assaults. A single FSR (24 hours food) is about 50% of the size and weight of three MREs. Each FSR provides 2,900 kcal (12,000 kJ) (15% protein, 53% carbohydrates, 34% fat), versus the 3,800 kcal (16,000 kJ) in three MREs, and has a two-year shelf life when stored at 80 °F (27 °C).
Sources: en.wikipedia.org
Novo (legally named Novo Nordisk A/S) is a Danish multinational pharmaceutical company. Novo manufactures and markets pharmaceutical products and services, primarily diabetes and obesity medications and devices. The corporation was created in 1989, through a merger of two Danish pharmaceutical companies, which date back to the 1920s. Novo employs approximately 68,800 people in 80 countries, and markets its products in approximately 170 countries. Novo is controlled by majority shareholder Novo Holdings (wholly owned by the Novo Nordisk Foundation) which holds approximately 28.1% of its shares and a majority (77.1%) of its voting shares. Novo is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA). The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo was named the most sustainable company in the world by the business magazine Corporate Knights. It is a leader in the FTSE4Good Index, and the only European company in the top ten. Novo is the largest pharmaceutical company in Denmark. Novo's market capitalization exceeded the GDP of Denmark's domestic economy in 2023, and it is the highest valued company in Europe.
== Types == The types of intrauterine devices available and the names they go by differ by location. The WHO ATC labels both copper and hormonal devices as IUDs. In the United Kingdom, there are more than 10 different types of copper IUDs available. In the United Kingdom, the term IUD refers only to these copper devices. Hormonal intrauterine contraception is labeled with the term intrauterine system (IUS). In the United States, there are two types available:
There were also communist states in Africa, such as Ethiopia. In 1974, the military overthrew Emperor Haile Selassie and installed a military junta known as the Derg. The Derg quickly aligned itself with the Soviet Union on the basis of communism, implementing Marxist-Leninist ideals that were radical for their country. The brutal imposition of their radical ideas led to a debilitating civil war. In 1977, after a series of political purges and executions, Mengistu Haile Mariam became the leader of the Derg. He continued this course and brought Ethiopia closer to the USSR, which became Ethiopia's main trading partner, supplying it with everything from weapons and equipment to military advisers and specialists. Mengistu ultimately built a highly militarized state with the largest army in sub-Saharan Africa. The Soviet Union pushed Mengistu to create a "People's Democratic" system, as was the case in the Eastern Bloc countries, but Mengistu did so very reluctantly: Ethiopia became the "People's Democratic Republic of Ethiopia" only in 1987. And although the Derg was formally dissolved, roughly the same people remained in power as before. In the other four existing socialist and people's democratic states, namely China, Cuba, Laos, and Vietnam, the ruling parties hold Marxism–Leninism as their official ideology, although they give it different interpretations in terms of practical policy. Marxism–Leninism is also the ideology of anti-revisionist, Hoxhaist, Maoist, and neo-Stalinist communist parties worldwide.
Sources: en.wikipedia.org
=== Purines === Phosphoribosyltransferases add activated ribose-5-phosphate (Phosphoribosyl pyrophosphate, PRPP) to bases, creating nucleoside monophosphates. There are two types of phosphoribosyltransferases: adenine phosphoribosyltransferase (APRT) and hypoxanthine-guanine phosphoribosyltransferase (HGPRT). HGPRT is an important enzyme in Purine pathway metabolism and its deficiency is implicated in Lesch–Nyhan syndrome.
The term "Holstein" derives from Old Saxon Holseta Land (Holz means wood in modern Standardized German; holt is a now-archaic English word for woods.) Originally, the term referred to the central of the three Saxon tribes north of the River Elbe: Tedmarsgoi (Dithmarschen), Holstein, and Sturmarii (Stormarn). The area inhabited by the tribe of the Holsts lay between the Stör River and Hamburg; after Christianization, their main church was in Schenefeld. Saxon Holstein became a part of the Holy Roman Empire after Charlemagne's Saxon campaigns in the late eighth century. Beginning in 811, the northern border of Holstein (and thus of the Empire) was the River Eider. The term "Schleswig" originally referred to the city of Schleswig. The word Schleswig is a German transliteration of the Danish word Slesvig, which consists of two words: Schlei and vig. The Schlei refers to the river at which the city lies, and vig means "inlet" or bay. Schleswig, therefore, means (in Danish): "The bay at the river Schlei". The Schlei is known as Slien in Danish and is believed to have been used only for the inner Slien (the Great and Little Bay near the city of Schleswig). The word is thought to be related to Slæ, which means reeds and aquatic plants found in this area. The Duchy of Schleswig, or Southern Jutland, was originally an integral part of Denmark, but in medieval times was established as a fief under the control of the Kingdom of Denmark, having the same relationship with the Danish Crown as, for example, Brandenburg or Bavaria had with the Holy Roman Emperor.
== Safety == A 2024 study of 35 traditional cottage industry gochujang products found that 8 samples (57% of tested products) exceeded the recommended limit of 4 log CFU/g for Bacillus cereus, a spore-forming bacterium that can produce emetic and diarrheal toxins. The same study also found that 57% of products contained alcohol levels exceeding 1%, which may be relevant for consumers following halal dietary guidelines. However, commercial gochujang produced under standardized manufacturing conditions generally shows lower levels of contamination and alcohol content. A 2015 survey of Korean fermented soybean products found that 13 of 23 gochujang samples tested positive for Bacillus cereus sensu lato, and all isolates carried at least one enterotoxin gene, though contamination levels did not exceed Korea's regulatory limit of 4 log CFU/g. A 2024 study detected aflatoxin in certain gochujang samples from different regions of Korea, with levels varying by geographic origin and fermentation conditions. One sample from Hongcheon contained 25.82 ± 0.66 µg/kg of total aflatoxin.
Delta 6 desaturase is an enzyme involved in converting essential fatty acids to arachidonic acid and prostaglandins, both of which are important to the functioning of cells. Infertility in women: One 2007 study found, "Each 2% increase in the intake of energy from trans unsaturated fats, as opposed to that from carbohydrates, was associated with a 73% greater risk of ovulatory infertility...". Major depressive disorder: Spanish researchers analysed the diets of 12,059 people over six years and found that those who ate the most trans fats had a 48 per cent higher risk of depression than those who did not eat trans fats. One mechanism may be trans-fats' substitution for docosahexaenoic acid (DHA) levels in the orbitofrontal cortex (OFC). Very high intake of trans-fatty acids (43% of total fat) in mice from 2 to 16 months of age was associated with lowered DHA levels in the brain (p=0.001). When the brains of 15 major depressive subjects who had committed suicide were examined post-mortem and compared against 27 age-matched controls, the suicidal brains were found to have 16% less (male average) to 32% less (female average) DHA in the OFC. The OFC controls reward, reward expectation, and empathy (all of which are reduced in depressive mood disorders) and regulates the limbic system. Behavioral irritability and aggression: a 2012 observational analysis of subjects of an earlier study found a strong relation between dietary trans fat acids and self-reported behavioral aggression and irritability, suggesting but not establishing causality.
Sources: en.wikipedia.org
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.
Most approved incretin therapies target one or two receptors, while retatrutide engages three. The addition of glucagon receptor activity is intended to raise energy expenditure. This broader mechanism is the subject of ongoing research rather than established practice.
No regulatory agency has approved retatrutide for any indication as of available public information. Development remains in later-stage trials. Availability claims found online should be treated as unverified.
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.